# Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

> **NCT00448539** · PHASE3 · TERMINATED · sponsor: **Eisai Inc.** · enrollment: 286 (actual)

## Conditions studied

- Refractory Partial Onset Seizures

## Interventions

- **DRUG:** Rufinamide

## Key facts

- **NCT ID:** NCT00448539
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-03-15
- **Primary completion:** 2010-05-14
- **Final completion:** 2010-05-14
- **Target enrollment:** 286 (ACTUAL)
- **Why stopped:** The study was terminated early by the sponsor due to the discontinuation of clinical development for rufinamide.
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00448539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00448539, "Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT00448539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*